New Weight-Loss Drug Shows Promise in Trial

<p>THURSDAY, May 10 (HealthDay News) A new weight-loss drug that
is accessible capitulation from a U.S. Food and Drug Administration showed
promising formula in a new general trial, researchers report.
Volunteers who took Qnexa, a multiple of a drugs phentermine and
topiramate, gifted estimable weight loss, even if they had many
weight-related health problems, a investigate found. The commentary were
reported this week during a European Congress on Obesity in Lyon,
France.
The 56-week clinical hearing enclosed 994 patients who took a placebo,
498 who took a middle sip of Qnexa, and 995 who took a high sip of the
drug.
Patients who took Qnexa had significantly larger weight detriment than
those who took a placebo, researchers Stephan Rossner, of a Karolinska
Institute in Stockholm, Sweden, and Arya Sharma, of a University of
Alberta in Edmonton, Canada, pronounced in a news recover from a European
Congress on Obesity.
Earlier this year, a U.S. Food and Drug Administration advisor...